| Methods |
Randomised controlled trial, open‐label |
| Participants |
Patients with neutropenia < 500/mm3, fever > 38.3 or > 38 in two measurements, without a focus of infection on admission. Mean age 40 (16‐69) yrs with all types of cancer |
| Interventions |
Teicoplanin 800 mg x 2 then 400 mg x 1 added to GP arm
Non‐intervention antibiotics: ceftazidime |
| Outcomes |
Failure
Mortality (all‐cause and infection‐related)
Superinfections
Adverse events |
| Notes |
Empirical design
Single centre, the Netherlands |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Low risk |
Computer‐generated randomisation |
| Allocation concealment (selection bias) |
Low risk |
Consecutive opaque and sealed envelopes |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
|
| Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
|
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Low risk for mortality, high risk for failure |
| Other bias |
High risk |
Patients included for different episodes and analysis by episode |
